BusinessOncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian CancerBy Nasdaq OMXFeb 13, 2017, 1:31 PM UTC
BusinessTesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian CancerBy Nasdaq OMXJan 17, 2017, 1:03 PM UTC
BusinessTesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian CancerBy Nasdaq OMXJan 17, 2017, 1:03 PM UTC
BusinessTesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian CancerBy Nasdaq OMXNov 1, 2016, 8:30 PM UTC
BusinessTESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMABy Nasdaq OMXOct 27, 2016, 8:10 PM UTC
BusinessTESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMABy Nasdaq OMXOct 27, 2016, 8:10 PM UTC
BusinessAdaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian CancerBy Nasdaq OMXOct 12, 2016, 1:15 PM UTC
BusinessTESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016By Nasdaq OMXOct 8, 2016, 6:15 AM UTC
